Optimized Basement Membrane Extracts for Organoid Growth and Xenograft Models
AMSBIO announces the availability of two new formulations of Basement Membrane Extract (BME) known as Cultrex BME 2 (organoid growth matrix) and Cultrex BME 3 (xenograft/tumorgraft matrix).
The new products have been developed to address the heterogeneous nature of tissue and organ micro-environments that not only arise from organ specific stromal cells, growth factors, proteoglycans, and protein composition but also from the stiffness or tensile strength of the BME. Many studies have shown that there is a relationship between abnormal tensile strength and both cancer progression and fibrotic tissues. It is both the chemical and physical properties of the BME that are responsible for the mechanical and biological properties of tissues and organs. It was in light of this heterogeneity that Cultrex BME 2 and Cultrex BME 3 were developed.
BME 2 is based upon a proprietary formulation that is higher in tensile strength than original Matrigel or Cultrex BME. This growth factor reduced product is recommended for organoid growth applications including 3D cell culture from stem cells. By comparison, BME 3 has been developed to be physiologically aligned with the in vivo tumour environment and is recommended for xenografts, tumorgrafts and other in vivo applications.
Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma. Basement membranes are degraded and regenerated during development and wound repair. They not only support cells and cell layers, but they also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. Basement membranes provide major barriers to invasion by metastatic tumour cells. Cultrex BME is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumours. The extract gels at 37 °C to form a reconstituted basement membrane. The major components of BME include laminin, collagen IV, entactin, and heparin sulphate proteoglycan. BME can be used for growth promotion or for the differentiation of precursor cells, under a variety of cell culture conditions, involving primary epithelial, endothelial and smooth muscle cells. BME has also been employed in cell attachment, neurite outgrowth, angiogenesis assays, in vitro cell invasion and in vivo tumorigenicity assays.
For further information on Cultrex BME 2 and Cultrex BME 3 please visit https://www.amsbio.com/
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...